🇺🇸 Zinc-l-carnosine in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 15

Most-reported reactions

1. Abdominal Pain Upper — 2 reports (13.33%)
2. Euglycaemic Diabetic Ketoacidosis — 2 reports (13.33%)
3. Fall — 2 reports (13.33%)
4. Hepatotoxicity — 2 reports (13.33%)
5. Vomiting — 2 reports (13.33%)
6. Asthenia — 1 report (6.67%)
7. Frequent Bowel Movements — 1 report (6.67%)
8. Gait Disturbance — 1 report (6.67%)
9. Gastrointestinal Pain — 1 report (6.67%)
10. Rib Fracture — 1 report (6.67%)

Source database →

Frequently asked questions

Is Zinc-l-carnosine approved in United States?

Zinc-l-carnosine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Zinc-l-carnosine in United States?

Fondazione IRCCS Policlinico San Matteo di Pavia is the originator. The local marketing authorisation holder may differ — check the official source linked above.